DEFA14A: Bionano Genomics Adjourns Special Meeting Again Due to Quorum Shortfall, Urges Stockholders to Vote

Bionano Genomics has adjourned its Special Meeting of Stockholders to November 27, 2024, due to a lack of quorum and is urging stockholders to vote on the proposal to issue common stock upon the exercise of warrants.

Summary

• Bionano Genomics adjourned its reconvened Special Meeting of Stockholders on October 30, 2024, due to the absence of a quorum.
• The meeting will reconvene on November 27, 2024, to allow stockholders more time to vote on the proposals outlined in the August 21, 2024 proxy statement.
• As of October 30, 2024, approximately 30.7% of total shares outstanding had submitted votes, falling short of the 33.3% required for a quorum.
• Of the votes submitted, approximately 76.3% were in favor of the proposal.
• The company emphasizes the importance of approving the proposal, as failure to do so could negatively impact its ability to raise capital and impair its operations.
• Stockholders are encouraged to vote 'For' the proposal, and those who have voted against it are asked to reconsider.
• The company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there's some support for the proposal, the adjournment due to lack of quorum and warnings about potential financial difficulties weigh heavily.

Positives

• Approximately 76.3% of the votes submitted were in favor of the proposal, indicating strong support among those who voted.

Negatives

• The Special Meeting was adjourned due to a lack of quorum, with only 30.7% of shares voted compared to the 33.3% required.
• Failure to approve the proposal could negatively impact the company's ability to raise capital and impair its operations.

Risks

• The company's future ability to raise equity or debt capital from third parties on attractive terms may be materially adversely affected if the proposal is not approved.
• Failure to approve the proposal also risks significantly impairing the operations, assets, and ongoing viability of the company.
• The company's ability to continue as a going concern depends on managing costs and obtaining significant additional financing.
• Adverse geopolitical and macroeconomic events, such as bank failures and the Ukraine-Russia conflict, could impact the business and global economy.

Future Outlook

The company's future depends on stockholders approving the proposal to issue common stock upon the exercise of warrants, which is crucial for raising capital and maintaining operations.

Management Comments

• Erik Holmlin, PhD, CEO of Bionano, stated that the company is grateful to stockholders who have voted and is pleased with the voting that has occurred.
• Erik Holmlin urges stockholders to vote 'For' the proposal and asks those who voted against it to reconsider.
• Erik Holmlin stated that the failure of stockholders to approve the proposal may materially adversely affect the company's future ability to raise capital and risks significantly impairing the company's operations.

Industry Context

Bionano operates in the genome analysis solutions market, providing tools for researchers and clinicians. The adjournment of the meeting and the need to secure stockholder approval for warrant exercises highlight the challenges faced by companies in this sector to secure funding and execute their strategic plans.

Stakeholder Impact

• Shareholders are urged to vote, as the outcome will impact the company's ability to raise capital.
• Employees' jobs could be at risk if the company cannot secure funding.
• The company's ability to serve its customers and partners may be affected if the proposal is not approved.

Next Steps

• The Special Meeting will reconvene on November 27, 2024.
• Stockholders are urged to vote on the proposal before November 26, 2024.

Key Dates

Keywords

Bionano Genomics, Special Meeting, Stockholders, Quorum, Vote, Proxy, Common Stock, Warrants, Capital Raise, Optical Genome Mapping, BNGO